MedPath

Laser Ablation in the Treatment of High-grade Cervical Lesions

Not Applicable
Not yet recruiting
Conditions
High-Grade Squamous Intraepithelial Lesions
Interventions
Procedure: LEEP or Conization
Procedure: laser ablation
Registration Number
NCT06333743
Lead Sponsor
Peking Union Medical College Hospital
Brief Summary

Cervical laser ablation is an effective, minimally invasive treatment with a low incidence of perinatal complications and minimal impact on fertility. Research has confirmed that laser ablation treatment of cervical HSIL (including CIN2 and CIN3) is effective and feasible and is useful for young CIN3 patients who wish to get pregnant in the future. There have been no randomized clinical trials of laser ablation therapy for cervical HSIL in Chinese women. This study focuses on the application of laser ablation in the treatment of cervical HSIL, explores the efficacy, feasibility, and safety of laser ablation in the treatment of cervical HSIL, and strives to promote the reasonable application of laser ablation in the treatment of cervical HSIL.

Detailed Description

1. Background This study focuses on the application of laser ablation in the treatment of cervical HSIL, explores the efficacy, feasibility, and safety of laser ablation in the treatment of cervical HSIL, and strives to promote the reasonable application of laser ablation in the treatment of cervical HSIL.

2. Research objects Young patients with cervical HSIL underwent colposcopic evaluation, completed cervical biopsy, and were pathologically confirmed to be eligible for ablation.

3. Methods 3.1 Sample size This study was a randomized controlled trial with parallel design. HSIL recurrence rate was the primary endpoint. According to previous literature reports, it is estimated that the recurrence rate of HSIL in the laser treatment group is 15%. The recurrence rate of HSIL in the resection group was 5%. Let α=0.05 (both sides), hold =0.80. Using PASS 11 software, the sample size of both groups was 138 cases. Assuming that the loss of follow-up rate of the study subjects was 10%, the sample size of each group was 138÷0.9=154 cases. Therefore, 308 patients were intended to be included in the study.

3.2 Statistical methods SPSS 24.0 software will be used for statistical analysis of all data. Measurement data with normal distribution will be described by mean ± standard deviation. Independent sample t-test or rank sum test will be used for inter-group comparison, and paired sample t-test will be used for intra-group comparison before and after treatment. Counting data will be expressed as examples or percentages (%), and the Chi-square test will be used for comparison between groups. The Kaplan-Meier method will be used to calculate the recurrence rate, and the rank sum test will be used to evaluate the difference between the two groups. Cox regression model will be used to analyze the factors influencing prognosis. P \< 0.05 will be considered statistically significant.

4. Results The primary endpoint is the HSIL recurrence rate at 12 months after treatment.

Other subjects were secondary study endpoints shown as follows:

Intraoperative and postoperative complications and side effects, including bleeding, pain, infection, cervical secretions, and healing; Psychological state change; Satisfaction; Cervical length; Recurrence rate; Fees

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
308
Inclusion Criteria
  1. < 40-year-old
  2. Cervical HSIL confirmed by colposcopic biopsy pathology
  3. Cervical transformation zone type 1 or 2
  4. The lesion is completely visible and does not extend into the cervical canal, and the lesion area is less than 50% of the cervical surface area
  5. Colposcopic evaluation ruled out invasive cancer
  6. Voluntary participation in the study with full and informed consent
Exclusion Criteria
  1. Cervical transformation zone type 3
  2. Glandular epithelial lesions
  3. Lesions greater than 50% of cervical surface area, or with vaginal and vulvar intraepithelial lesions
  4. The upper margin of the lesion was not visible or extended into the cervical canal
  5. Cervical tube sampling was diagnosed with CIN2+ or CIN that could not be graded
  6. Cervical biopsy is not sufficient to confirm a tissue diagnosis
  7. Suspected invasive cancer
  8. History of cervical surgery
  9. Pregnancy or planning a pregnancy during study participation
  10. Autoimmune or immune deficiency diseases
  11. Long-term use of immunosuppressive drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LEEP or conization treatmentLEEP or ConizationThe cervix was stained with iodine solution and the diseased lesion was visualized. LEEP or conization was performed to a depth of approximately 1.5 cm to resect disease in the cervical canal.
laser ablation treatmentlaser ablationLaser vaporization is performed using a carbon dioxide laser under colposcopy. All patients received 1% mepivacaine hydrochloride paracervix block. No general anesthesia was used. Before laser vaporization began, scaly columnar nodules were visible in all patients. The evaporation depth is 8-10mm, and the edge is 5mm from the abnormal discovery or transition area.
Primary Outcome Measures
NameTimeMethod
the rate of HSIL recurrence12 months after treatment

12 months after the treatment, TCT, HPV, colposcopy, and biopsy will be tested again. If the result of the biopsy is HSIL again, we will record it as HSIL recurrence.

Secondary Outcome Measures
NameTimeMethod
the satisfaction with the treatment8 weeks and 12 months after treatment

after the treatment, patients will fill in a questionnaire to describe their degree of satisfaction with the treatment

Psychological state change related to the treatment8 weeks and 12 months after treatment

State-Trait Anxiety Inventory,STAI-Form Y will be used to measure the patients' psychological state after treatment.

the length of the cervix8 weeks and 12 months after treatment

the length of the cervix will be measured by B-ultrasound

© Copyright 2025. All Rights Reserved by MedPath